Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/21083

Title: A meta-analysis of biological variation in blood-based therapy as a precursor to bio-manufacturing
Authors: Thurman-Newell, Jamie A.
Petzing, Jon N.
Williams, David J.
Keywords: Biological variation
Blood
HSCT
Process design
Quality control
Issue Date: 2016
Publisher: Elsevier (© International Society for Cellular Therapy)
Citation: THURMAN-NEWELL, J., PETZING, J. and WILLIAMS, D., 2016. A meta-analysis of biological variation in blood-based therapy as a precursor to bio-manufacturing. Cytotherapy, 18 (5), pp.686-694.
Abstract: Currently cellular therapies, such as hematopoietic stem cell transplantation (HSCT), are produced at a small scale on a case-by-case basis, usually in a clinical or near-clinical setting. Meeting the demand for future cellular therapies will require a robust and scalable manufacturing process that is either designed around or controls the variation associated with biological starting materials. Understanding variation requires both a measure of the allowable variation (that does not negatively affect patient outcome) and the achievable variation (with current technology). The prevalence of HSCT makes it an ideal case study to prepare for more complex biological manufacturing with more challenging regulatory classifications. A systematic meta-analysis of the medical literature surrounding HSCT has been completed of which the key outcomes are the following: (i) the range of transplanted CD34+ cells/kg can be up to six orders of magnitude around the median for allogeneic procedures and four orders of magnitude for autologous procedures, (ii) there is no improvement in variation encountered over a period of 30 years and (iii) as study size increases, the amount of variation encountered also increases. A more detailed, stratified source from a controlled single-site clinical center is required to further define a control strategy for the manufacture of biologics.
Description: THIS ITEM WILL REMAIN CLOSED ACCESS UNTIL 06/04/2017.
Sponsor: Funding for this work was provided by the UK Engineering and Physical Sciences Research Council (Grant EP/FS00491/1) as part of the Doctoral Training Centre for Regenerative Medicine.
Version: Accepted for publication
DOI: 10.1016/j.jcyt.2016.01.011
URI: https://dspace.lboro.ac.uk/2134/21083
Publisher Link: http://dx.doi.org/10.1016/j.jcyt.2016.01.011
ISSN: 1465-3249
Appears in Collections:Closed Access (Mechanical, Electrical and Manufacturing Engineering)

Files associated with this item:

File Description SizeFormat
Cytotherapy Prepublication manuscript.pdfAccepted version660.41 kBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.